← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV14행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastalePhase 1
nivolumab (Opdivo, Motolimod + Nivolumab)
Presage Biosciences·HNSCC
1 trials
Overview
Program
Motolimod + Nivolumab
Overview
Company
Presage Biosciences
Overview
Modality
ANTIBODY
Overview
Target
HNSCC
Overview
Indication
HNSCC
Overview
Phase
PHASE_1
Overview
Status
DISCONTINUED
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Toxicology
Major finding
Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma.. Head and neck squamous cell carcinoma (HNSCC) has an estimated annual global death rate of approximately 300,000. Despite advances in surgical techniques, the advent of efficient radiation delivery methods, and the introduction of newer chemotherapeutic agents, the survival rate for HNSCC has alarmingly remained…
Clinical
Safety signal
Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma.. Head and neck squamous cell carcinoma (HNSCC) has an estimated annual global death rate of approximately 300,000. Despite advances in surgical techniques, the advent of efficient radiation delivery methods, and the introduction of newer chemotherapeutic agents, the survival rate for HNSCC has alarmingly remained…
Clinical
Program phase
PHASE_1